In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37011390.
- Also identified by DOI 10.7326/J23-0020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. <b>Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial.</b> JAMA. 2023;329:39-51. 36525245.
Medical subject headings
- COVID-19